The system is based upon the discovery that the health of cell membranes reflects the overall health of the patient and detects any disease condition before lab studies; imaging techniques and physical examination can see them
Harrisville, MI (Vocus) August 31, 2009
IPGDx, LLC; a Michigan medical technology development company, is now offering patients, families and physicians a ‘Biometric Scoring System’ for prognosis based upon a noninvasive diagnostic test that objectively, accurately and immediately illustrates how serious a disease condition is and if treatment is working (so it can be improved if possible).
“The system is based upon the discovery that the health of cell membranes reflects the overall health of the patient and detects any disease condition before lab studies; imaging techniques and physical examination can see them”, said Michaeal Singer, President of the Company. “The information can be used to measure the benefits of treatment and determine recovery. The test electrically illustrates the cell membrane looking ‘up-stream’ in the process of physiology to a level that occurs earlier than usual tests. By providing better information sooner the results can be used by patients, families and physicians to make superior healthcare decisions in any disease condition including cancer, heart disease, diabetes, pulmonary disorders, hepatitis and more.”
- Detect the presence of illness at its earliest occurrence so the patient can seek care, treatment can begin sooner and be more effective
- Characterize the severity of illness to alert the physician and better allocate resources
- Evaluate the effectiveness of treatment and allow it to be changed or optimized for the needs of the individual patient
- Illustrate the individual patient’s ‘Burden of Disease’; the cumulative effect of all the events and conditions that brought the patient to where they are right now
- Confirm where the patient is on the trajectory of their illness, if what is being done is working and if recovery is possible
- Objectively support the transition from curative or restorative goals to palliative care
- Be used right now!
While a diagnosis can almost always be made, treatment is always given but prognosis is seldom known. Statistical reports and evaluation of even all the variables don’t illustrate what an individual patient will experience. Each patient should be considered individually and evaluated dynamically, over time as changes occur (disease progresses, treatment works (or not)). The Company found that even the most educated and experienced clinicians’ prognosis is wrong eight out of ten times; which is why they are rarely given. Consider what your own experience has been for yourself or your family; has it been satisfying or not; could it have been made better?
Independent publications (attached) answer the following questions; the Company has shown the technology can be used to better manage our healthcare.
- How sick is this patient, how severe is this illness?
- What are the chances; complete partial or no recovery?
- Could this illness have been found sooner?
- Is this treatment working, can it be made to be more effective, is it worth enduring?
- What is going to happen next?
- Considering the costs (time, side effects and money) of the proposed treatments and the likelihood of a positive outcome how best do I decide to undergo this treatment?
- As a patient, what am I willing to do, if this ends my time; where do I want to be, should I endure treatment that takes the quality from the time I have left?
- As a family member what is the right thing to do?
- As a physician do I have enough information to make the best decision for this patient?
“In the upcoming influenza epidemic the severity of the disease can be seen and reported by PrognostiCheck® and guide the patient to the level of care they need sooner and easier; the test can even be done at home” said Dr John Kutzko, Co-President of the Company. “The PrognostiCheck® results come from a simple noninvasive test that is quickly done has no side effects and is easily repeated to show change over time. It is especially sensitive to changes and precise with nearly perfect test; re-test reliability; (0.98 out of 1). The device used for the test is an FDA 510(k) approved Class II medical instrument. PrognostiCheck® is a ‘Biometric Scoring System’ in a software program, not a medical device and not regulated by the FDA. The test is inexpensive to complete (~$5.00), takes just a few minutes and the professional instrument cost is $3,500.00. The Company, IPGDx, LLC is now ready to sell and support the use of the ‘Professional PrognostiCheck® System’ and is seeking funding to build a ‘Consumer’ or home device next year.”
More information including a bibliography of publications in various diseases is available on the Company’s website at http://www.ipgdx.com or email the Company at firstname.lastname@example.org.
The Company is six years old and holds exclusive license to the patents from inventors Singer & Kutzko with offices in FL and MI.